Inactive Instrument

Champignon Brands Stock price Canadian Securities Exchange

Equities

SHRM

CA15850D1006

Healthcare Facilities & Services

Sales 2022 1.49 2.02 Sales 2023 1.88 2.55 Capitalization 6.59M 8.93M
Net income 2022 -12M -16.26M Net income 2023 -13M -17.62M EV / Sales 2022 2,322,657 x
Net cash position 2022 8.46M 11.47M Net cash position 2023 1.26M 1.7M EV / Sales 2023 2,832,851 x
P/E ratio 2022
-0.87 x
P/E ratio 2023
-0.43 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 56.58%
More Fundamentals * Assessed data
Dynamic Chart
Braxia Scientific Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Braxia Scientific Corp. Announces Board Changes CI
Braxia Scientific Corp. Announces CFO Changes CI
Braxia Scientific Corp. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Braxia Scientific Corp. Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Braxia Scientific Corp. Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Braxia Scientific Provides Operations Update MT
Irwin Naturals Launches New Product in Canada MT
Irwin Naturals Brief: Says Cannabis Products Launch Nationwide in Canada MT
Irwin Naturals Closes Purchase of Ketamine Media MT
Irwin Naturals Brief: CEO of Irwin Naturals, Klee Irwin, Expressed Disappointment on the Announcement, But Recognized the Decision was "Based on a Lack of a Clear Business Rationale for the Company to move forward with the Transaction" MT
Irwin Naturals Brief: Says has terminated Non-binding amended and restated letter of intent for a business combination with Braxia Scientific Corp. MT
Irwin Naturals Inc. cancelled the acquisition of Braxia Scientific Corp.. CI
Braxia Scientific Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Braxia Scientific Corp. announced that it has received CAD 0.513 million in funding CI
More news
Managers TitleAgeSince
Chief Executive Officer - 20-05-10
Director of Finance/CFO - 21-01-07
Chief Tech/Sci/R&D Officer - 22-07-03
Members of the board TitleAgeSince
Director/Board Member 67 19-08-18
Chief Executive Officer - 20-05-10
Director/Board Member - 21-01-31
More insiders
Braxia Scientific Corp. is a Canada-based company, which is primarily focused on owning and operating multidisciplinary clinics, providing treatment for mental health disorders, and research activities related to discovering and commercializing drugs and delivery methods. The Company seeks to develop ketamine and derivatives and other psychedelic products from its Internet protocol (IP) development platform. The Company has clinic operations in the Canadian cities of Mississauga, Toronto, Kitchener-Waterloo, Ottawa and Montreal. The Company, through its wholly owned subsidiary, the Canadian Rapid Treatment Center of Excellence Inc., it operates multidisciplinary community-based clinics offering rapid-acting treatments for depression located in Mississauga, Toronto, Ottawa, Kitchener and Montreal. Its subsidiaries include Altmed Capital Corp., Artisan Growers Ltd., KetaMD, Inc., Novo Formulations Ltd. and Tassili Life Sciences Corp.
More about the company
  1. Stock
  2. Equities
  3. Stock Braxia Scientific Corp.
  4. Stock Champignon Brands - Canadian Securities Exchange